Brickell Biotech, Inc. (BBI): Price and Financial Metrics

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing On track to report SAD and MAD topline results from FRTX-02 Phase 1 study by early 2023 BOULDER, Colo., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“FRTX” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and groundbreaking prescription therapeutics for

Yahoo | September 13, 2022

Brickell Biotech changes name to Fresh Tracks Therapeutics

• Clinical-stage biotech Brickell Biotech, Inc. (NASDAQ:BBI) announced a major rebranding exercise on Wednesday, renaming its corporate identity to Fresh Tracks Therapeutics, Inc.
• Accordingly, the company said that BBI’s name, logo, website, and branding would change to reflect the company’s new strategic shift towards autoimmune, inflammatory, and other diseases.
• In line with the rebranding, the company’s common stock will begin trading under the new Nasdaq ticker symbol “FRTX” from Thursday.
• Meanwhile, in connection with the rebranding, the company has formed a Sc...

  Seeking Alpha | September 7, 2022

Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics

New name, logo, website, and branding reflect the Company’s strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol “FRTX” on September 8, 2022 Company also establishes Scientific Advisory Board consisting of renowned autoimmune and inflammatory disease experts to provide strategic guidance for the research and development of FRTX’s novel pipeline BOULDER, Colo., Sept. 07, 2022 (GLOBE NEWSWIRE) --

Yahoo | September 7, 2022

Analysts Offer Insights on Healthcare Companies: Brickell Biotech (BBI), Phio Pharmaceuticals (PHIO) and Albireo Pharma (ALBO)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Brickell Biotech (BBI – Research Report), Phio Pharmaceuticals (PHIO – Research Report) and Albireo Pharma (ALBO – Research Report) with bullish sentiments. Brickell Biotech (BBI) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Brickell Biotech today and set a price target of $4.50. The company's shares closed last Monday at $3.50, close to its 52-week low of $2.88. According to TipRanks.

Howard Kim on TipRanks | August 16, 2022

Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developin

Yahoo | August 11, 2022